5 completed, 3 recruiting, 1 terminated. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Recruiting 3, Terminated 1 |
| Phase 2 | 4 | Completed 2, Recruiting 2 |
Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer | Phase 1 / Phase 2 | Recruiting | Nimbus Wadjet, Inc. | 134 | 2025-03-31 | 2026-05-06 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers ATX-559 - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Terminated | Accent Therapeutics | 17 | 2024-10-11 | 2026-02-24 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors VVD-133214, Pembrolizumab, Bevacizumab - Advanced Solid Tumors, Colorectal Cancer | Phase 1 | Recruiting | Vividion Therapeutics, Inc. | 280 | 2024-01-25 | 2026-11-12 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors FT500, Nivolumab, Pembrolizumab - Advanced Solid Tumors, Lymphoma | Phase 1 | Completed | Fate Therapeutics | 37 | 2019-02-15 | 2023-05-01 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies INCAGN02385 - Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer | Phase 1 | Completed | Incyte Biosciences International Sàrl | 22 | 2018-06-18 | 2020-10-30 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors APL-501 - Solid Tumor, Microsatellite Instability | Phase 1 | Completed | Apollomics (Australia) Pty. Ltd. | 30 | 2017-03-27 | 2022-05-09 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers MK-3475, INCB024360 - Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 444 | 2014-07-17 | 2022-02-14 |
Colorectal Neoplasms (4) · Melanoma (4) · Stomach Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Merkel Cell (3) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3) · Head and Neck Neoplasms (3) · Small Cell Lung Carcinoma (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2)
Genomic Instability (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Neoplasms (7) · Gastrointestinal Neoplasms (6) · Neoplasms by Site (6) · Colonic Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Intestinal Diseases (5)
pembrolizumab (3) · Bevacizumab (1) · Cyclophosphamide (1) · Docetaxel (1) · Interleukin-2 (1) · Irinotecan (1) · Nivolumab (1) · aldesleukin (1) · atezolizumab (1) · bintrafusp alfa protein, human (1) · epacadostat (1) · fludarabine (1)
Accent Therapeutics (1) · Apollomics (Australia) Pty. Ltd. (1) · Fate Therapeutics (1) · Incyte Biosciences International Sàrl (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · Marengo Therapeutics, Inc. (1) · Nimbus Wadjet, Inc. (1) · Vividion Therapeutics, Inc. (1)
United States (8) · Australia (3) · Canada (3) · France (3) · Spain (3) · United Kingdom (2) · Belgium (1) · China (1) · Denmark (1) · Ireland (1) · Malaysia (1) · Portugal (1) · South Korea (1)
Anita Scheuber, MD, PhD (1) · John Janik, MD (1) · Marietta Franco (1) · Mark Jones, MD (1) · Van K Morris, MD (1)
2023 (2)